Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, finds.
Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug Wegovy for a common type of heart failure, saying that
August 7, 2024